On Tuesday, December 28, Union Health Minister Mansukh Mandaviya stated that the Centre had accorded emergency use authorization approval to two vaccines and an antiviral drug to fight the prevalent, COVID-19 pandemic, reports stated.
Mandaviya took to Twitter to elaborate on how the Central Drugs Standard Control Organisation (CDSCO) and the health ministry has given three approvals in one day for CORBEVAX vaccine, COVOVAX vaccine and anti-viral drug Molnupiravir. This is being undertaken for restricted use in an emergency situation he said.
Congratulations India 🇮🇳
— Dr Mansukh Mandaviya (@mansukhmandviya) December 28, 2021
Further strengthening the fight against COVID-19, CDSCO, @MoHFW_INDIA has given 3 approvals in a single day for:
- CORBEVAX vaccine
- COVOVAX vaccine
- Anti-viral drug Molnupiravir
For restricted use in emergency situation. (1/5)
According to reports, the approval comes a day after the Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommends giving the emergency use authorization to them. Whilst Covovax will be curated by the Serum Institute of India, Corbevax will be made by the Biological-E.
Mandaviya remarked that Corbevax is India’s first indigenously developed RBD protein sub-unit vaccine against coronavirus.
Additionally, 13 companies in the country will manufacture Molnupiravir, Merck's Covid-19 pill. This will be utilized to treat patients who are adults and have a high risk of progression of the disease.
With this, eight vaccines have attained emergency use authorization. The country will commence vaccinating those between 15 – 18 years of age from January 3. Similarly, precautionary shots to healthcare and frontline workers as well as those over the age of 60 with comorbidities from January 10.
Also Read: Omicron Scare: 11 New Cases Detected In Mumbai, Including 1.5-Year-Old Girl From UK
Share
Tweet
